Cellectis S.A.
CLLS
Rank in Stocks
#20395
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Share Price
$1.12
Last synced: 2026-11-09
Market Cap
$85.31M
Change (1 day)
4.67%
Change (1 year)
-69.89%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cellectis S.A. (CLLS)
Category
Healthcare
Operating Margin for Cellectis S.A. (CLLS)
Operating Margin as of November 2026 TTM: -107.92%
According to Cellectis S.A.'s latest financial reports, its current operating margin (TTM) is -107.92%. At the end of 2025 the company had an operating margin of -55.32%.
Operating Margin history for Cellectis S.A. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -107.92% | 95.08% |
| 2025 | -55.32% | -61.44% |
| 2024 | -143.48% | -98.89% |
| 2023 | -12,887.68% | 2,655.43% |
| 2022 | -467.72% | 304.81% |
| 2021 | -115.54% | 0.00% |
| 2020 | -115.54% | -85.80% |
| 2019 | -813.38% | -1.46% |
| 2018 | -825.47% | 124.42% |
| 2017 | -367.83% | 144.89% |
| 2016 | -150.20% | 170.83% |
| 2015 | -55.46% | 128.70% |
| 2014 | -24.25% | -93.14% |
| 2013 | -353.35% | 275.98% |
| 2012 | -93.98% | -23.02% |
| 2011 | -122.09% | 67.98% |
| 2010 | -72.68% | -6.72% |
| 2009 | -77.92% | 139.90% |
| 2008 | -32.48% | -82.88% |
| 2007 | -189.73% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.36% |
US
|
|
| -149.01% | -98.62% |
US
|
|
| 25.57% | -100.24% |
AU
|
|
| 31.23% | -100.29% |
BE
|
|
| 29.35% | -100.27% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cellectis S.A.'s operating margin
What is Cellectis S.A.'s operating margin?
Cellectis S.A.'s operating margin is -107.92%, as of Nov 2026.
What was Cellectis S.A.'s operating margin in 2025?
In 2025, Cellectis S.A.'s operating margin was -55.32%, compared with -143.48% in 2024.
How has Cellectis S.A.'s operating margin changed since 2020?
From 2020 to 2025, Cellectis S.A.'s operating margin was highest in 2025 (-55.32%) and lowest in 2023 (-12,887.68%).
How does Cellectis S.A.'s operating margin compare with similar companies?
Cellectis S.A.'s operating margin (-107.92%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.